VANTA DIAGNOSTICS™ is a market leader in providing targeted, molecular diagnostics that can improve clinical and economic outcomes.
Making responsible decisions on when and how to prescribe antibiotic therapy.
The CDC has stated that at least 30% of antibiotics prescribed in the US are either unnecessary or inappropriate. The other 70% is still in need of further customization in choosing the appropriate dosing due to the variability in metabolization and drug absorption.
In 2019, we are also experiencing a shortage in antibiotics, which is propelling the antibiotic resistance crisis into a true global epidemic.
The scholars of a white paper by the Dutch non-profit organization, Access to Medicine recently stated that lack of access to specific antibiotics can lead to less appropriate antibiotics being prescribed for an infection, the use of lower doses or delays in treatment.
Source: Access to Medicine Foundation
Antibiotic Stewardship
- Appropriate Antibiotic Guidance
- Assess changes in bacterial resistance
- Improve transmission defense protocols
- Monitoring the risk of potential outbreaks
At present, more than 100 drugs, including a number of antibiotics, are listed by the US Food and Drug administration as being in short supply.
Source: The Guardian
A comprehensive resistence gene testing panel
Vanta Diagnostics uses a unique, data-driven approach that combines precise, molecular pathogen and resistance gene detection with sensitivity and susceptibility data.
Through the addition of infection management guidance with each result report, Vanta Diagnostics infectious disease panels support clinicians in providing a more targeted and customized treatment plan for their patients within 24 hours of the patient sample arriving at our lab. This guidance may consider the patient’s age, comorbidities, allergies, concomitant medications, regional susceptibility patterns in addition to the test results.
Vanta Diagnostics offers the most comprehensive Resistance Gene Testing Panel on the market today. Vanta Diagnostics’ resistance panel currently identifies up to 49 resistance genes in up to 13 antibiotic classes that could lead to ineffective antibiotic therapy, including the genes for the enzymes associated with ESBL, which can have even worse outcomes than MRSA.
Where can I go for updates and information?
Vanta Diagnostics is investing in resources to support your Antibiotic Stewardship programs to include:
- Rapid and Accurate Diagnostics
- Patient Population Analytics
- Clinical Trial Data focused on Better Outcomes
- Education and Awareness Tools
Download Antibiotic Resistance poster (PDF)
Download the National Action Plan (PDF)